TY - JOUR
TI - Reply to the letter to the editor ‘Utilisation of the ESMO-MCBS in practice of HTA’ by Wild et al.
AU - Cherny, N.I.
AU - Sullivan, R.
AU - Dafni, U.
AU - Bogaerts, J.
AU - Kerst, J.M.
AU - Zielinski, C.
AU - Piccart, M.J.
AU - De Vries, E.G.E.
JO - Annals of Oncology
PY - 2016
VL - 27
TODO - 11
SP - 2136-2137
PB - Oxford University Press
SN - 0923-7534, 1569-8041
TODO - 10.1093/annonc/mdw406
TODO - epidermal growth factor receptor;  gefitinib;  ipilimumab;  nivolumab;  protein tyrosine kinase inhibitor;  trametinib;  vemurafenib, adverse outcome;  biomedical technology assessment;  EGFR gene;  feedback system;  gene mutation;  general condition deterioration;  health care utilization;  human;  Letter;  lung cancer;  medical decision making;  medical society;  metastatic melanoma;  non small cell lung cancer;  oncology;  overall survival;  peer review;  priority journal;  progression free survival;  public health service;  quality of life;  risk factor;  therapy effect
TODO - null
ER -